Cellular Pharmacology of 9-(β-D-1,3-dioxolan-4-yl) Guanine and its Lack of Drug Interactions with Zidovudine in Primary Human Lymphocytes

Abstract

Amdoxovir, currently in Phase II clinical trials, is rapidly converted to 9-(β-D-1,3-dioxolan-4-yl)guanine (DXG) by adenosine deaminase in vitro and in humans. The cellular pharmacology of DXG in primary human lymphocytes, including dose-response relationships, intracellular half-life of DXG triphosphate (DXG-TP), and combination studies were determined. DXG produced high levels of DXG-TP with a long half-life (16 h) in activated human peripheral blood mononuclear cells. Since zidovudine (ZDV) and DXG select for different resistance mutations, co-formulation of the these two drugs is an attractive proposition. A combination study between DXG and ZDV showed no reduction of DXG-TP or ZDV-TP. Taken together, these results suggest that an appropriately designed DXG prodrug could be given once a day and that co-formulation with ZDV might be a possibility.

Keywords

cellular pharmacology DXG nucleoside analogues NRTI

References

Bazmi

Hammond

Cavalcanti

Chu

Schinazi

& Mellors

(2000) In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′deoxythymidine. Antimicrobial Agents Chemotherapy 44: 1783–1788.

Chin

Shaw

Torresi

Sozzi

Trautwein

Bock

Manns

Isom

Furman

& Locarnini

(2001) In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabino-furanosyluracil. Antimicrobial Agents Chemotherapy 45: 2495–2501.

Wainberg

Nguyen-Ba

L'Heureux

De Muys

Bowlin

& Rando

(1999) Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrobial Agents Chemotherapy 43: 2376–2382.

Mewshaw

Myrick

Wakefield

Hooper

Harris

McCreedy

& Borroto-Esoda

(2002) Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. Journal of Acquired Immune Deficiency Syndromes 29: 11–20.

Seigneres

Pichoud

Martin

Furman

Trepo

& Zoulim

(2002) Inhibitory activity of dioxolane purine analogues on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36: 710–722.

Ying

De Clercq

Nicholson

Furman

& Neyts

(2000) Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. Journal of Viral Hepatitis 7: 161–165.